1stOncology™: Cancer Intelligence Service – Page 112 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

On January 6, 2026 Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, reported a strategic collaboration with Pfizer to discover tumor-selective antigens. Under the multi-year agreement, Cartography will apply its proprietary ATLAS and SUMMIT discovery platforms to identify and validate tumor-selective antigens in an undisclosed indication. Pfizer may opt in on multiple antigens identified and validated through this collaboration and will be responsible for all research, development and commercialization of programs directed to selected antigens. Cartography’s lead program, CBI-1214, remains wholly owned and independently advanced by the company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A core component of the collaboration is the target analysis and identification capabilities of Cartography’s ATLAS and SUMMIT platforms. ATLAS and SUMMIT utilize a proprietary approach to a longstanding challenge in oncology: identifying antigens that precisely target cancer cells while sparing the vast landscape of cells in the healthy body. By comprehensively analyzing antigen expression across the full spectrum of healthy and tumor cell states, ATLAS and SUMMIT can identify antigens and combinations of antigens with optimal tumor selectivity. Cartography’s platforms integrate expansive patient-derived datasets with advanced computational biology, antigen validation, and antibody engineering.

Kevin Parker, CEO of Cartography Biosciences. "Our ATLAS and SUMMIT platforms are designed to uncover target biology that traditional tools simply cannot resolve, enabling the nomination of highly tumor-selective antigens and antigen pairs with potential to significantly improve therapeutic precision and patient outcomes. We are excited to collaborate with Pfizer, whose deep scientific, development and regulatory expertise positions them as an ideal partner."

Under the terms of the collaboration, Cartography is eligible to receive up to $65M in upfront payment, near-term milestone payments, and option exercise payments. The agreement carries a potential total deal value exceeding $850 million if all options are exercised, with Cartography eligible to receive future development, regulatory, and commercial milestones, as well as tiered royalties on net sales for any programs Pfizer advances under the collaboration.

(Press release, Cartography Biosciences, JAN 6, 2026, View Source [SID1234661744])

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

On January 5, 2026 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, reported that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference, in San Francisco. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Wednesday, January 14, at 11:15 a.m. PT and host investor meetings throughout the conference.

A webcast of the presentation will be available here on the Investors section of the Company’s website.

(Press release, Rocket Pharmaceuticals, JAN 5, 2026, View Source [SID1234661740])

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

On January 5, 2026 Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, reported that it has entered into definitive agreements with a single healthcare-focused institutional investor for the purchase and sale of shares of common stock, par value $0.0001 per share ("Common Stock") and pre-funded warrants (the "Pre-Funded Warrants") in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor, investor warrants (the "PIPE Common Warrants"). Aggregate gross proceeds to the Company from both transactions are expected to be approximately $8.0 million. The entire transaction has been priced at-the-market under applicable Nasdaq rules. The transactions consisted of the sale of 5,063,290 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant to purchase one (1) share of Common Stock and (ii) one and one-half (1.5) PIPE Common Warrants (for a total of 7,594,935 PIPE Common Warrants). Each PIPE Common Warrant is exercisable for one (1) share of Common Stock at an exercise price of $1.39. The offering price per Common Unit is $1.58 (or $1.5799 for each Pre-Funded Unit, which is equal to the offering price per Common Unit sold in the offering minus the $0.00001 exercise price of the Pre-Funded Warrants). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Unit sold in the offering, the number of Common Units in the offering will be decreased on a one-for-one basis.

The transactions are expected to close on or about January 6, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital.

Aegis Capital Corp. is acting as exclusive placement agent for the offerings. Winston & Strawn LLP is acting as counsel to the Company. Sichenzia Ross Ference Carmel LLP is acting as counsel to Aegis Capital Corp.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-283770) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on December 19, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at [email protected], or by telephone at +1 (212) 813-1010.

The offer and sale of the securities in the private placement are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the Common Stock and the Shares issuable upon exercise of the Pre-Funded Warrants and PIPE Common Warrants.

Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Estrella Biopharma, JAN 5, 2026, View Source [SID1234661739])

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

On January 5, 2026 Vir Biotechnology, Inc. (Nasdaq: VIR), reported that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, reported it will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

(Press release, Vir Biotechnology, JAN 5, 2026, View Source [SID1234661738])

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

On January 5, 2026 NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported the Company will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

NeoGenomics’ management is scheduled to present and participate in a Q&A session on Tuesday, January 13, at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at ir.neogenomics.com.

(Press release, NeoGenomics Laboratories, JAN 5, 2026, View Source [SID1234661737])